"biocon-biologics"

The company also secured European Commission authorisation, enabling the launch across the EU and EEA regions

Denosumab biosimilars Vevzuo and Evfraxy are used for treating various bone diseases. The approvals mark a key step in the company’s European expansion and reinforce its commitment to affordable biologic therapies

Company says biosimilar Bevacizumab will be manufactured at its new multi-product monoclonal antibodies drug substance facility in Bengaluru

Biocon Biologics has entered into a definitive agreement with Viatris Inc to acquire its biosimilars business to create a fully integrated global biosimilars enterprise, Biocon Ltd said in a statement.